Nitrogen Or Sulfur Patents (Class 424/78.27)
-
Patent number: 7794696Abstract: Degradable complexes comprising a polycation, a polyanion and a polynucleotide are useful for in vivo polynucleotide delivery applications.Type: GrantFiled: September 21, 2004Date of Patent: September 14, 2010Assignee: Nitto Denko CorporationInventors: Sang Van, Jiadong Zhou, Xiaoli Fu, Lei Yu
-
Patent number: 7771711Abstract: The present invention concerns novel sphingolipid-polyalkylamines conjugates, a process for their preparation and pharmaceutical compositions comprising the same. In particular, the present invention concerns ceramide based polyalkylamine conjugates and its use as a capturing agent. A preferred ceramide polyalkylamine conjugate is a ceramide-spermine conjugate, more preferably, N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine.Type: GrantFiled: June 17, 2004Date of Patent: August 10, 2010Assignees: Yissum Research Development Company of The Hebrew University of Jerusalem, Biolab Ltd.Inventors: Yechezkel Barenholz, Dmitri Simberg, Elimelech Rochlin
-
Patent number: 7772357Abstract: A water soluble polymer comprising multiple degradable carbonate linkages in a backbone and, for each carbonate linkage in the backbone, an oligomer linked thereto by the carbonate linkage, wherein the oligomer is branched.Type: GrantFiled: September 14, 2009Date of Patent: August 10, 2010Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Michael D. Bentley, Xuan Zhao, Xiaoming Shen
-
Patent number: 7754782Abstract: The present invention relates to novel, rapidly curing adhesives based on hydrophilic polyisocyanate prepolymers for use in surgery.Type: GrantFiled: June 30, 2008Date of Patent: July 13, 2010Assignee: Bayer Material Science AGInventors: Heike Heckroth, Burkhard Köhler, Sebastian Dörr
-
Patent number: 7741454Abstract: The crosslinking agents and condensing agents that have been employed in biological adhesives and in treating medical devices such as cardiac valves are non-natural compounds synthesized artificially. Thus, they are not metabolized in vivo and exhibit toxicity to living bodies. These compounds are thus used only in a restricted amount and for limited purposes in the clinical sites. The present invention provides a biological low-molecular-weight derivative obtained by modifying carboxyl groups of a biological low-molecular-weight compound with N-hydroxysuccinimide, N-hydroxysulfosuccinimide, or a derivative thereof and a crosslinked high-molecular-weight product obtained by crosslinking various high-molecular-weight compounds with this derivative.Type: GrantFiled: September 11, 2003Date of Patent: June 22, 2010Assignees: National Institute for Materials Science, Furuuchi Chemical CorporationInventors: Tetsushi Taguchi, Hisatoshi Kobayashi, Junzo Tanaka, Hirofumi Saito
-
Publication number: 20100136077Abstract: The present invention discloses household cleaning materials comprising at least one insoluble proton sink or source (PSS) and to method for utilizing the PSS as a biocidic agent. The household cleaning materials are provided useful for killing living target cells (LTCs) or otherwise inhibiting LTCs growth, disrupting vital intracellular processes and/or intercellular interactions of the LTC upon contact. The household cleaning materials consisting of at least one PSS, comprises, inter alia, (i) proton source or sink providing a buffering capacity; and (ii) means providing proton conductivity and/or electrical potential. The PSS is effectively disrupting the pH homeostasis and/or electrical balance within the confined volume of said LTC and/or disrupting vital intercellular interactions of said LTCs while efficiently preserving the pH of said LTCs' environment.Type: ApplicationFiled: April 3, 2008Publication date: June 3, 2010Applicant: OPLON B.V.Inventors: Shmuel Bukshpan, Gleb Zilberstein
-
Patent number: 7705185Abstract: Alkylated antioxidant macromolecules are represented by Structural Formula 1: wherein the variables are described herein. Also included are methods of making the molecules and methods of using the molecules as antioxidants.Type: GrantFiled: March 24, 2006Date of Patent: April 27, 2010Assignee: Polnox CorporationInventors: Rajesh Kumar, Ashok L. Cholli
-
Publication number: 20100062968Abstract: The present invention provides biodegradable particles (e.g., three-dimensional particles) and micelles which can be used to encapsulate active agents for delivering to a subject. The present invention further provides methods for producing and delivering such particles and micelles. Additionally, the invention provides vaccination strategies that encompass the use of the novel particles and micelles.Type: ApplicationFiled: May 10, 2006Publication date: March 11, 2010Inventors: Bali Pulendran, Niren Murthy, Robert H. Pierce, Michael John Heffernan, Jihua Hao, Marcin Kwissa
-
Patent number: 7674452Abstract: Polymers and methods of making them are described. The polymers may be used to coat living cells. The polymer-coated cells are useful in cell therapy applications.Type: GrantFiled: February 22, 2006Date of Patent: March 9, 2010Assignee: Nitto Denko CorporationInventors: Sang Van, Yasunobu Tanaka, Lei Yu
-
Patent number: 7662365Abstract: The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.Type: GrantFiled: January 17, 2006Date of Patent: February 16, 2010Assignee: Nektar TherapeuticsInventors: Michael David Bentley, Michael James Roberts, Xiaoming Shen, Lin Cheng
-
Publication number: 20100003212Abstract: The present invention relates to novel articles and the like, typically exhibiting antimicrobial efficacy which articles contain for example a carrier, a spacer attached to the carrier and one or more quaternary ammonium groups attached directly or indirectly to said spacer.Type: ApplicationFiled: June 25, 2007Publication date: January 7, 2010Inventors: Georg L. Kis, Benoit Pugin, Barbel Fobel
-
Patent number: 7625552Abstract: According to an aspect of the present invention, bioactive polymers are provided which have (a) a hydrophilic bioactive portion and (b) at least one hydrophobic polymer group that is linked to the hydrophilic bioactive portion by a covalent linkage that contains a chain transfer agent residue. According to another aspect of the present invention, medical articles are provided with bioactive surface by coating them with a coating material that contains such bioactive polymers.Type: GrantFiled: May 30, 2006Date of Patent: December 1, 2009Assignee: Boston Scientific Scimed, Inc.Inventors: Michael N. Helmus, Paul Valint, Shrirang V. Ranade
-
Patent number: 7608678Abstract: A water soluble polymer is described, the water soluble polymer comprising multiple hydrolytically degradable carbonate linkages in a backbone and, for each carbonate linkage in the backbone, an oligomer linked thereto by the carbonate linkage, wherein the oligomer is branched and, prior to being linked by the carbonate linkage, has the formula: R3[O—(—CHR1CH2—O—)n—]mH where R3 is a core branching moiety, R1 is H, (n) can range from 2 to 2000, and m is at least 3.Type: GrantFiled: August 3, 2007Date of Patent: October 27, 2009Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Michael D. Bentley, Xuan Zhao, Xiaoming Shen
-
Patent number: 7597882Abstract: Some aspects of this disclosure relate to a method for crosslinking a biological fluid comprising combining a biological fluid with a crosslinker to covalently crosslink proteins endogenous to the biological fluid to form a crosslinked gel. Examples of a biological fluid are blood, plasma, or serum.Type: GrantFiled: April 24, 2007Date of Patent: October 6, 2009Assignee: Incept LLCInventors: Chandrashekhar P. Pathak, Amarpreet S. Sawhney, James H. Dreher
-
Patent number: 7588754Abstract: Condensation polymerization methods are used to prepare various biodegradable polyacetals of the general formula (I). Such polymers are useful for variety of drug, biomolecule and imaging agent delivery applications.Type: GrantFiled: May 10, 2005Date of Patent: September 15, 2009Assignee: Nitto Denko CorporationInventors: Sang Van, Hyun Sik Chae, Lei Yu
-
Patent number: 7547765Abstract: The present invention provides a branched polyalkylene glycol wherein three or more single-chain polyalkylene glycols and a group having reactivity with an amino acid side chain, the N-terminal amino group or the C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity are bound; and a physiologically active polypeptide modified with the branched polyalkylene glycol.Type: GrantFiled: October 23, 2007Date of Patent: June 16, 2009Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Motoo Yamasaki, Toshiyuki Suzawa, Tatsuya Murakami, Noriko Sukurai, Kinya Yamashita, Mayumi Mukai, Takashi Kuwabara
-
Publication number: 20090136443Abstract: The present invention has an object of providing a drug carrier capable of controlling in vivo pharmacokinetics. The present invention is directed to a drug carrier comprising a molecular assembly having a drug incorporated therein, and the above object can be achieved by a part of the amphiphilic molecules included in the molecular assembly being released from the molecular assembly by an external environmental change. The present invention utilizes a phenomenon that the hydrophilic-hydrophobic balance of the amphiphilic molecules is shifted toward hydrophilicity by an external environmental change and thus the amphiphilic molecules are freed from the molecular assembly.Type: ApplicationFiled: March 10, 2006Publication date: May 28, 2009Applicants: Oxgenix Co., Ltd., WASEDA UNIVERSITYInventors: Shinji Takeoka, Yosuke Okamura, Hideo Kanazawa, Shuji Hisamoto, Kohei Kubota, Yosuke Obata
-
Patent number: 7534907Abstract: A monomer composition comprising at least one polymerizable alkyl ester ?-cyanoacrylate monomer. Specifically, the ?-cyanoacrylate monomer is an alkyl ester ?-cyanoacrylate monomer of the general formula having a spacer R1: n is from 2 to 12; R3 and R4 are each an alkyl group or a hydrogen, and at least one of R3 or R4 is an alkyl group (e.g. linear or branched, or cyclic) having from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 carbon atoms; R2 is an alkyl group (e.g. linear or branched, or cyclic) having from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 carbon atoms; and the combined number of carbon atoms (N) in the spacer R1 is at least n+1.Type: GrantFiled: May 30, 2007Date of Patent: May 19, 2009Assignee: Ethichon, Inc.Inventor: Hongbo Liu
-
Patent number: 7534852Abstract: An aromatic polyanhydride comprising a repeating unit having the structure is disclosed, wherein Ar and R are selected so that the aromatic polyanhydride hydrolyzes to form a therapeutic salicylate, another non-steroidal anti-inflammatory, an antifibrotic aminobenzoate, or a vasoconstricting phenylethanolamine. Implantable medical devices, such as scaffolding implants for tissue reconstruction, drug delivery systems prepared from the aromatic polyanhydrides, as well as therapeutic dosage forms and treatment methods are also disclosed.Type: GrantFiled: September 6, 2006Date of Patent: May 19, 2009Assignee: Rutgers, The State University of New JerseyInventor: Kathryn E. Uhrich
-
Publication number: 20090098083Abstract: The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.Type: ApplicationFiled: August 15, 2008Publication date: April 16, 2009Inventors: Jeffrey A. Hubbell, Donald Elbert, Ronald Schoenmakers
-
Publication number: 20090011004Abstract: This invention relates to drug delivery and specifically to the preparation and use of functionalized carriers such as nanopolymers and nanovesicles for improved delivery of nucleic acid agents (NAA) to tissues and cells. These compounds have broad applicability for treating numerous diseases and disorders, including neurodegenerative and neuromuscular disorders. The concept encompasses preferably polymeric carriers for delivery of a class of oligonucleotides that modulate RNA splicing.Type: ApplicationFiled: January 2, 2007Publication date: January 8, 2009Applicant: Philadelphia Health & Education Corp., D/B/A/ Drexel University of College of MedicineInventors: Gordon John Lutz, Margaret Alison Wheatley
-
Patent number: 7442370Abstract: A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.Type: GrantFiled: January 31, 2003Date of Patent: October 28, 2008Assignee: Biogen Idec MA Inc.Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Paula Ann Boriack-Sjodin, Stephan S. Miller, Anthony Rossomando, Laura Silvian
-
Publication number: 20080226583Abstract: Polymers (i.e. polyesters, polyamides, and polythioesters or a mixture thereof) which degrade hydrolytically into biologically active compounds are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver biologically active compounds to a host are also provided.Type: ApplicationFiled: December 13, 2007Publication date: September 18, 2008Inventor: Kathryn E. Uhrich
-
Publication number: 20080152616Abstract: The present invention relates to an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block with a terminal hydroxyl group wherein the terminal hydroxyl group of the hydrophobic bock is substituted with a tocopherol or cholesterol group. It also relates to polymeric compositions capable of forming stable micelles in an aqueous solution, comprising the amphiphilic block copolymer and a polylactic acid derivative wherein one or more ends of the polylactic acid are covalently bound to at least one carboxyl group.Type: ApplicationFiled: October 10, 2007Publication date: June 26, 2008Inventors: Min Hyo Seo, Sa-Won Lee, Myung-Han Hyun, Jeong-Il Yu, Dong-Hoon Chang, Hye-Jeong Yoon, Jeong-Kyung Kim
-
Publication number: 20080124299Abstract: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.Type: ApplicationFiled: October 30, 2007Publication date: May 29, 2008Inventors: Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Katherine E. Henderson
-
Publication number: 20080118460Abstract: The instant invention provides a novel conjugate of a synthetic, biodegradable, exceedingly hydrophilic and non-proteinaceous polymer, whereby each of the above attributes is defined in the specification, and various pharmacologically active agents. The instant invention also provides methods for the identification of said polymers, and methods for the preparation of conjugated pharmaceutically active agents. Furthermore, the invention provides a novel polymer blend for use in pharmaceutical and health care products and applications.Type: ApplicationFiled: November 5, 2007Publication date: May 22, 2008Inventors: Evgeny Vulfson, Jeffrey W. Hare
-
Publication number: 20080112891Abstract: An encapsulated chelate dendritic polymer and an encapsulated ligand dendritic polymer are disclosed which have unique properties. These encapsulated chelate dendritic polymers may have associated with its dendritic polymer surface target directors, proteins, DNA, RNA (including single strands) or any other moieties that will assist in diagnosis, therapy or delivery of this encapsulated chelate dendritic polymer. These encapsulated dendritic polymers are suitable as contrast agents for use in imaging in an animal, for other imaging techniques, for EPR, and as scavenger agents for chelant therapy. Formulations for these uses are also included within the scope of this invention.Type: ApplicationFiled: February 15, 2006Publication date: May 15, 2008Applicant: Dendritic Nanotechnologies, Inc.Inventors: Donald A. Tomalia, Baohua Huang
-
Publication number: 20080112918Abstract: A method for treating gout and/or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer, for example, an aliphatic amine polymer. In one embodiment, the polymer binds to uric acid or a precursor thereof. Examples of polymers useful in an embodiment of the invention include sevelamer hydrochloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that binds serum uric acid in a patient.Type: ApplicationFiled: June 18, 2007Publication date: May 15, 2008Inventors: Stephen Randall Holmes-Farley, Steven K. Burke
-
Publication number: 20080112917Abstract: The present invention concerns novel sphingolipid-polyalkylamines conjugates, a process for their preparation and pharmaceutical compositions comprising the same. In particular, the present invention concerns ceramide based polyalkylamine conjugates and its use as a capturing agent. A preferred ceramide polyalkylamine conjugate is a ceramide-spermine conjugate, more preferably, N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine.Type: ApplicationFiled: June 17, 2004Publication date: May 15, 2008Applicants: BIOLAB LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Yechezkel Barenholz, Dmitri Simberg, Elimelech Rochlin
-
Publication number: 20080107618Abstract: Mast cell (MC) and peripheral blood basophil (PBB)-associated diseases are treated or prevented, or their symptoms are alleviated by the administration of water soluble fullerenes (buckeyballs) to the individual under conditions sufficient to inhibit MC and PBB responses. MC and PBB responses are associated with, for example, various allergies including Type 1 hypersensitivity initiated by IgE-antigen, arthritis, multiple sclerosis, urticaria, atopic dermatitis, heart disease, etc. The treatment regimen can be enhanced using Chimeric fullerenes that specifically home to and inhibit MC and PBB cells. These molecules, for example, comprise fullerenes to which are attached IgE Fc or stem cell factor (SCF) peptides that bind to receptors specifically on MC and PBB cells. Additional molecules which may be used in the processes include IgE Fc or SCF peptides with several fullerenes covalently attached.Type: ApplicationFiled: September 26, 2006Publication date: May 8, 2008Inventor: Chris KEPLEY
-
Publication number: 20080057024Abstract: A composition including a solution suitable for introduction into a blood vessel comprising particles including a treatment agent and a tunable stimuli-responsive polymer. A method including introducing a delivery device into a blood vessel; and introducing a solution into the blood vessel, the solution including particles comprising a treatment agent and a tunable stimuli-responsive polymer. A method including combining a treatment agent and a tunable stimuli-responsive polymer; and forming particles of the combination suitable for delivery through a blood vessel.Type: ApplicationFiled: August 30, 2006Publication date: March 6, 2008Inventors: Gina Zhang, Jessica Renee DesNoyer, Gordon Stewart, Maricela Kezis, Syed Faiyaz Ahmed Hossainy
-
Publication number: 20080025943Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.Type: ApplicationFiled: July 31, 2006Publication date: January 31, 2008Inventors: Eugene Michal, Olof Mikael Trollsas, Shubhayu Basu
-
Patent number: 7316811Abstract: The invention provides a multi-arm block copolymer for use in delivering a variety of bioactive agents. The copolymer of the invention contains a central core from which extend multiple (3 or more) copolymer arms. Each copolymer arm possesses an inner polypeptide segment and an outer hydrophilic polymer segment. Thus, the overall structure of the copolymer comprises an inner core region that includes the central core and the inner polypeptide segment, while the outer core region is hydrophilic in nature. The multi-arm copolymer of the invention is particularly useful for delivery of biologically active agents that can be entrapped within the inner core region.Type: GrantFiled: December 24, 2003Date of Patent: January 8, 2008Assignee: Nektar Therapeutics AL, CorporationInventors: Xuan Zhao, Zhongxu Ren, Kazunori Emoto
-
Publication number: 20080003253Abstract: A block copolymer comprising a methoxyethyl methacrylate (MOEMA) midblock is provided for forming a coating a medical device for controlled release of a bioactive agent.Type: ApplicationFiled: June 29, 2006Publication date: January 3, 2008Inventor: Thierry Glauser
-
Patent number: 7311901Abstract: The present invention relates to an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block with a terminal hydroxyl group wherein the terminal hydroxyl group of the hydrophobic bock is substituted with a tocopherol or cholesterol group. It also relates to polymeric compositions capable of forming stable micelles in an aqueous solution, comprising the amphiphilic block copolymer and a polylactic acid derivative wherein one or more ends of the polylactic acid are covalently bound to at least one carboxyl group.Type: GrantFiled: October 7, 2004Date of Patent: December 25, 2007Assignee: Samyang CorporationInventors: Min Hyo Seo, Bong Oh Kim, In Ja Choi, Myung Seob Shim
-
Publication number: 20070286885Abstract: A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided.Type: ApplicationFiled: June 9, 2006Publication date: December 13, 2007Inventors: Syed F. A. Hossainy, Mikael Trollsas, Thierry Glauser, Yiwen Tang
-
Publication number: 20070274945Abstract: A chelation structure and method of forming and using the chelation structure. The chelation structure has a backbone that includes a linear sequence of monomeric backbone units, at least one polymer side chain, and at least one chelator side chain. The side chains are each covalently coupled to the backbone at one of the monomeric backbone units by a bond that is independently biodegradable or non-biodegradable. The chelation structure is synthesized by Radical Addition Fragmentation Transfer (RAFT), Atom Transfer Radical Polymerization (ATRP), or Free Radical Polymerization (FRP). The chelation structure, individually or in combination with a shuttle chelator, may be introduced into a mammal to bind an amount of a substance in a mammal, the substance being at least one of a metal and heme. The chelation structure has a log stability constant exceeding that of the shuttle chelator for binding the substance within cells of the mammal.Type: ApplicationFiled: May 25, 2006Publication date: November 29, 2007Inventors: Mark D. Scott, Jayachandran N. Kizhakkedathu
-
Publication number: 20070264226Abstract: Synergistically enhanced disinfecting solutions comprising sodium chlorite in the range of 10 about ppm to about 5000 ppm and myristamidopropyl dimethylamine in the range of about 0.05 ppm to about 500 ppm for. In addition, synergistically enhanced disinfecting solutions comprising myristamidopropyl dimethylamine in the range of 0.05 ppm to 500 ppm and polyhexamethylene biguanide in the range of about 0.01 ppm to about 100 ppm for.Type: ApplicationFiled: May 8, 2007Publication date: November 15, 2007Inventors: Hampar L. Karagoezian, John Park
-
Publication number: 20070258941Abstract: A therapeutic method and compositions are provided that involve injection of a cation solution into extracellular matrix of a tissue. In the preferred embodiment, a percutaneous (performed through the skin) injection of a polylysine solution into the nucleus of a herniated disc is provided, to reduce intradiscal pressure.Type: ApplicationFiled: May 1, 2007Publication date: November 8, 2007Inventor: Brian E. Pfister
-
Patent number: 7291713Abstract: The present invention provides a branched polyalkylene glycol wherein three or more single-chain polyalkylene glycols and a group having reactivity with an amino acid side chain, the N-terminal amino group or the C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity are bound; and a physiologically active polypeptide modified with the branched polyalkylene glycol.Type: GrantFiled: January 30, 2002Date of Patent: November 6, 2007Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Motoo Yamasaki, Toshiyuki Suzawa, Tatsuya Murakami, Noriko Sakurai, Kinya Yamashita, Mayumi Mukai, Takashi Kuwabara
-
Publication number: 20070248567Abstract: Some aspects of this disclosure relate to a method for crosslinking a biological fluid comprising combining a biological fluid with a crosslinker to covalently crosslink proteins endogenous to the biological fluid to form a crosslinked gel. Examples of a biological fluid are blood, plasma, or serum.Type: ApplicationFiled: April 24, 2007Publication date: October 25, 2007Inventors: Chandrashekhar P. Pathak, Amarpreet S. Sawhney, James H. Dreher
-
Publication number: 20070237741Abstract: A method for medical treatment was developed in which microspheres with novel properties are administered in a mammal. The microspheres are made using a novel process that results in microspheres with new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres may be administered for void filling, tissue bulking, non-vasculature occlusion, body fluid absorption, and delivery of medications.Type: ApplicationFiled: April 5, 2007Publication date: October 11, 2007Inventors: Garret D. Figuly, Surbhi Mahajan, Rinaldo S. Schiffino, Sujata K. Bhatia, Elazer R. Edelman, Tarek Michael Shazly, Michael Jordan Feldstein
-
Publication number: 20070185216Abstract: This invention provides a method of inactivating non-enveloped virus particles. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof.Type: ApplicationFiled: February 1, 2007Publication date: August 9, 2007Inventors: MARCIA SNYDER, David R. Macinga, James W. Arbogast
-
Publication number: 20070184016Abstract: This invention provides a pre-surgical disinfecting composition that includes at least about 50 percent by weight of a C1-6 alcohol, based upon the total weight of the disinfecting composition, an acid, and a cationic oligomer or polymer. A method for pre-surgical skin disinfection with rapid antiseptic efficacy without the use of secondary antimicrobial compounds is also described.Type: ApplicationFiled: December 29, 2006Publication date: August 9, 2007Inventors: David R. Macinga, Marcia Snyder, James W. Arbogast
-
Patent number: 7238828Abstract: A monomer composition comprising at least one polymerizable alkyl ester ?-cyanoacrylate monomer. Specifically, the ?-cyanoacrylate monomer is an alkyl ester ?-cyanoacrylate monomer of the general formula having a spacer R1: wherein n is from 2 to 12; R3 and R4 are each an alkyl group or a hydrogen, and at least one of R3 or R4 is an alkyl group (e.g. linear or branched, or cyclic) having from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 carbon atoms; R2 is an alkyl group (e.g. linear or branched, or cyclic) having from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 carbon atoms; and the combined number of carbon atoms (N) in the spacer R1 is at least n+1.Type: GrantFiled: March 24, 2005Date of Patent: July 3, 2007Assignee: Ethicon, Inc.Inventor: Hongbo Liu
-
Publication number: 20070148127Abstract: An ophthalmic treatment system comprises an ophthalmic treatment solution and a biguanide antimicrobial agent in solid form and in contact with said treatment solution such as to inhibit bacterial and/or fungal growth in said solution. The biguanide is partially or wholly terminated with an amine compound.Type: ApplicationFiled: December 15, 2006Publication date: June 28, 2007Inventors: David J. Heiler, Joseph C. Salamone, Richard V. Smerbeck, Matthew S. Jonasse
-
Patent number: 7226586Abstract: Extremely hydrophobic nitric oxide (NO) releasing polymers are disclosed. The extremely hydrophobic NO-releasing polymers provided are extensively cross-linked polyamine-derivatized divinylbenzene diazeniumdiolates. These polymers can be loaded with extremely high NO levels and designed to release NO in manners than mimic natural biological systems. The NO-releasing extremely hydrophobic polymers provided can maintain a sustained NO release for periods exceeding nine months. Also provided are related medical devices made using these NO-releasing extremely hydrophobic polymers.Type: GrantFiled: July 17, 2003Date of Patent: June 5, 2007Assignee: Medtronic Vascular, Inc.Inventors: Anthony L. Fitzhugh, Robert Cafferata, Larry K. Keefer
-
Patent number: 7208145Abstract: Polymeric reagents comprising a polymer attached, either directly or through one or more atoms to a ketone or a related functional group such as ketone hydrate, thione, monothiohydrate, dithiohydrate, hemiketal, monothiohemiketal, dithiohemiketal, ketal, or dithioketal are provided. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.Type: GrantFiled: December 31, 2003Date of Patent: April 24, 2007Assignee: Nektar Therapeutics AL, CorporationInventors: Samuel P. McManus, Antoni Kozlowski, Xiaoming Shen, Daniel C. Cook
-
Patent number: 7083634Abstract: The present invention is directed to adhesive/hemostatic formulations of 2-alkoxyalkyl cyanoacrylate, an absorbable liquid or solid polymeric modifier, and a general stabilizer against premature anionic polymerization of cyanoacrylates. The present adhesive formulations are useful as tissue adhesives/sealants, hemostatic agents, or as a means of patching and anastomotic coupling of damaged organs.Type: GrantFiled: November 20, 2002Date of Patent: August 1, 2006Assignee: Poly Med IncInventor: Shalaby W. Shalaby
-
Patent number: 7074459Abstract: A method for preserving wood which comprises contacting the wood with a complex of a cationic monomeric or polymeric biocide and an anionic monomeric or polymeric biocide. Insoluble complexes may solubilized in water in the form of an emulsion or microemulsion by adding a nonionic and/or amphoteric surfactant and/or aqueous cosolvent to the complex. Suitable cationic biocides are those that contain functionalities such as amidine, guanidine, biguanide, quaternary, phosphonium, sulfonium and gemini quaternary functionalities. Suitable anionic biocides include: phenolics; saturated, unsaturated or substituted carboxylates; organomercaptide; tetrathiocarbonates; cyanodithioimidocarbamates; dithiodialkylcarbamates; anionic oxides of transition metals; aminocarboxylic acids; aminoorganophosphonic acids; monoalkyl phosphates; dialkylphosphates; and substituted or unsubstituted 2-hydroxy-2,4,6-cycloheptatrianone.Type: GrantFiled: May 23, 2003Date of Patent: July 11, 2006Inventor: Richard F. Stockel